Related references
Note: Only part of the references are listed.Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial
Fergus Macbeth et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data The PRISMA-IPD Statement
Lesley A. Stewart et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial
Uwe Pelzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Prevention of VTE in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Susan R. Kahn et al.
CHEST (2012)
Low-Molecular-Weight Heparin Versus Placebo for the Prevention of Venous Thromboembolism in Metastatic Breast Cancer or Stage III/IV Lung Cancer
Sylvia K. Haas et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2012)
Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer
A. Maraveyas et al.
EUROPEAN JOURNAL OF CANCER (2012)
Routine Heparin for Patients with Cancer? One Answer, More Questions
Elie A. Akl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Randomized Trial of the Effect of the Low Molecular Weight Heparin Nadroparin on Survival in Patients With Cancer
Frederiek F. van Doormaal et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prediction of venous thromboembolism in cancer patients
Cihan Ay et al.
BLOOD (2010)
PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma
J. R. Perry et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Adjuvant bemiparin in small cell lung cancer: results from the ABEL study
R. Lecumberri et al.
THROMBOSIS RESEARCH (2010)
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study
Giancarlo Agnelli et al.
LANCET ONCOLOGY (2009)
Development and validation of a predictive model for chemotherapy-associated thrombosis
Alok A. Khorana et al.
BLOOD (2008)
Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study
Catherine Weber et al.
SUPPORTIVE CARE IN CANCER (2008)
Heparin-induced thrombocytopenia: A review
Bruno Girolami et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2006)
Low-molecular-weight heparin in patients with advanced cancer: A phase 3 clinical trial
Kostandinos Sideras et al.
MAYO CLINIC PROCEEDINGS (2006)
The effect of low molecular weight heparin on survival in patients with advanced malignancy
CPW Klerk et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Electronic alerts to prevent venous thromboembolism among hospitalized patients
N Kucher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Meta-analysis of individual patient data from randomized trials: a review of methods used in practice
MC Simmonds et al.
CLINICAL TRIALS (2005)
Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test
ST Brookes et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2004)
A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer
M Altinbas et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic)
T McGinn et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2004)
Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS)
AK Kakkar et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Can low-molecular-weight heparins improve outcome in patients with cancer?
P Thodiyil et al.
CANCER TREATMENT REVIEWS (2002)
Multilevel models for meta-analysis, and their application to absolute risk differences
SG Thompson et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2001)
Subgroup analysis and other (mis)uses of baseline data in clinical trials
SF Assmann et al.
LANCET (2000)
Share Paper
